Certara (NASDAQ:CERT) Releases FY24 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of $0.41-0.44 for the period, compared to the consensus EPS estimate of $0.41. The company issued revenue guidance of $380-385 million, compared to the consensus revenue estimate of $386.66 million. Certara also updated its FY 2024 guidance to 0.410-0.440 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CERT shares. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Barclays lowered their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $15.92.

Certara Stock Performance

NASDAQ:CERT traded up $0.04 during mid-day trading on Friday, reaching $11.03. The stock had a trading volume of 1,081,810 shares, compared to its average volume of 786,430. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.61 and a current ratio of 2.61. The business has a 50 day simple moving average of $11.02 and a 200 day simple moving average of $13.70. Certara has a twelve month low of $9.99 and a twelve month high of $19.87. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of -22.06, a PEG ratio of 4.88 and a beta of 1.51.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.06 earnings per share. On average, analysts expect that Certara will post 0.27 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Certara news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.